2Okamoto H, Watanabe K. Medical Treatment for StageⅢ Non-Small-Cel (NSCLC) [J]. Gan To Kagaku Ryo- ho,2007, 34(6): 842-848.
3Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regi- mens of paclitaxel and carboplatin forlocally advanced non-small-cell lung cancer: A randomized phase Ⅱ locally advanced multi-modality protocol[J]. J Clin Oncol, 2005, 23 (25) : 5883- 5891.
4Grnberg BH, Bremnes RM, Fl+tten O, et al. Phase Ⅲ study by the Nor- wegian lung cancer study group: pemetrexed plus carboplatin com- pared with gemcitabine plus carbopla- tin as first-line chemotherapy in ad- vanced non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(19): 3217- 3224.
5Bischof M, Weber KJ, Blatter J, et al. Interaction of pemetrexed disodi- urn (ALIMTA, multitargeted antifo- late) and irradiation in vitro[J]. Int J Radiat Oncol Biol Phys,2002, 52(5) : 1381-1388.
6Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of peme- trexed, carboplatin, and conncurrent radiotherapy in patients with lacally advanced or metastatic non-small cell lung or esophageal cancer [J ]. Clin Cancer Res, 2007, 13(2 pt 1): 515- 522.
9Shen X, Denittis A, Werner-Wasik M, et al. Phase i study of ,dose dense peme trexed plus carboplatin/ radio therapy ~or locally-advanced non - small-cell lung carcinoma [J].Radiot Oncol, 2011,6:17.
4Mountain CF. Revisions in the international system for staging lung cancer [J]. Chest, 1997, 111 (6): 1710.
5Perez CA, Pajak TF, Rubin P, et al. Long - term observations of the patterns of failure in patients with unresectable non - oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group [J]. Cancer, 1987, 59 (11):1874.
6Chen M, Jiang G, Fu X, et al. Prognostic factors for local control in non small - cell lung cancer treated with definitive radiation therapy [J]. Am J Clin Oncol (CCT), 2002, 25 (1):76.
7Dillman RO, Seagren SL, Propert K J, et al. A randomized trial of induction chemotherapy plus high - dose radiation versus radiation alone in stage III non - small - cell lung cancer [J]. N Engl J ned, 1990, 323 (14):940.
8Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage m non - small - cell lung cancer: 7 - year follow - up of cancer and leukemia group B (CALGB)8433 trial [J]. J Natl Cancer Inst, 1996, 88 (17) : 1210.
9Sause W, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88 -08 and Eastern Cooperative Oncology Group (ECOG) 4588 : Preliminary results of a phase m trial in regionally advanced, unresectable non- small - cell lung cancer [ J]. J Natl Cancer Inst, 1995, 87 (3): 198.
10Sause W, Kolesar P, Taylor S, et al. Final resuhs of phase III trial in regionally advanced unresectable non- small cell lung cancer Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group [J]. Chest, 2000, 117 (2):358.
5Lopez Guerra JL, Gomez D,Zhuang Y, et al. Change in diffusing capacity after radiation as an objective measure for grading radia- tion pneumonitis in patients treated for non-small cell lung canc- er[ J ]. Int J Radiat Oncol Biol Phys, 2012, 83:1573-1579.
6Guo NL, Wan YW. Pathway-based identification of a smoking associated 6-gene signature predictive of lung cancer risk and survival[J]. Artif Intell Medi, 2012, 55:97-106.
